Literature DB >> 27677625

The C'JAAD: a French team for early intervention in psychosis in Paris.

Alice Oppetit1,2,3, Julie Bourgin1,2,3, Gilles Martinez1,2,3, Mathilde Kazes1,2,3, Célia Mam-Lam-Fook1,2,3, Raphael Gaillard1,2,3, Jean-Pierre Olié1,2,3, Marie-Odile Krebs1,2,3.   

Abstract

AIM: The aim is to describe a centre operating in Paris that pioneers the early intervention for young people at the onset and at high risk of psychosis in France.
METHODS: Comprehensive descriptive analysis of different clinical and service measures is used in describing the implementation of the C'JAAD (Evaluation Centre for Young Adults and Adolescents) using data from an ongoing prospective non-interventional research programme.
RESULTS: Over a 2-year period, 151 patients were referred to the C'JAAD and included in the ICAAR research programme. After evaluation by the Comprehensive Assessment of the At-Risk Mental States Scale, 53.7% were identified at risk of developing a psychosis, 20.6% presented a full-blown psychosis and 25.7% were considered not at risk of developing a psychosis. A total of 84% of the at-risk subjects suffered from a psychiatric co-morbidity, of which anxiodepressive symptoms being the most frequent (39%). The global functioning of these at-risk subjects was seriously impaired (average Social and Occupational Functioning Assessment Scale score = 48.9). More than one third of the patients was self-referred (33.8%), 22.5% were addressed by a psychiatrist whereas 10.6% were referred by a general practitioner.
CONCLUSIONS: In this paper, we report for the first time the activities of the C'JAAD, the pioneer unit in France for early detection and treatment of young adults with early psychosis. These observations indicate that such early intervention centre is a feasible and sustainable extension of traditional care for people with mental disorders in this country and offers promising perspective for the development of further centres.
© 2016 John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  early detection; mental health services; prevention; prodromal symptoms; schizophrenia

Mesh:

Year:  2016        PMID: 27677625     DOI: 10.1111/eip.12376

Source DB:  PubMed          Journal:  Early Interv Psychiatry        ISSN: 1751-7885            Impact factor:   2.732


  6 in total

1.  Stress, Cortisol and NR3C1 in At-Risk Individuals for Psychosis: A Mendelian Randomization Study.

Authors:  Anton Iftimovici; Oussama Kebir; Qin He; Thérèse M Jay; Guy A Rouleau; Marie-Odile Krebs; Boris Chaumette
Journal:  Front Psychiatry       Date:  2020-07-10       Impact factor: 4.157

2.  Longitudinal Analyses of Blood Transcriptome During Conversion to Psychosis.

Authors:  Boris Chaumette; Oussama Kebir; Juliette Pouch; Bertrand Ducos; Fekrije Selimi; Raphael Gaillard; Marie-Odile Krebs
Journal:  Schizophr Bull       Date:  2019-01-01       Impact factor: 9.306

3.  Psychosis risk research versus daily prognosis uncertainties: A qualitative study of French youth psychiatrists' attitudes toward predictive practices.

Authors:  Laelia Benoit; Marie Rose Moro; Bruno Falissard; Nicolas Henckes
Journal:  PLoS One       Date:  2017-07-19       Impact factor: 3.240

4.  Epigenetic variability in conversion to psychosis: novel findings from an innovative longitudinal methylomic analysis.

Authors:  Oussama Kebir; Boris Chaumette; Marie-Odile Krebs
Journal:  Transl Psychiatry       Date:  2018-04-26       Impact factor: 6.222

5.  Ensemble programme for early intervention in informal caregivers of psychiatric adult patients: a protocol for a randomised controlled trial.

Authors:  Shyhrete Rexhaj; Shadya Monteiro; Philippe Golay; Claire Coloni-Terrapon; Daniel Wenger; Jérôme Favrod
Journal:  BMJ Open       Date:  2020-07-30       Impact factor: 2.692

6.  Implementing the Latvian Early Intervention Program (LAT-EIP) for Patients With Schizophrenia Spectrum First-Episode Psychosis: Study Protocol.

Authors:  Liene Berze; Sandra Civcisa; Ilona Krone; Dmitrijs Kvartalovs; Sarmite Kikuste; Inna Sapele; Jelena Lazovika; Elmars Rancans
Journal:  Front Psychiatry       Date:  2019-11-13       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.